Results 41 to 50 of about 150,246 (305)

Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy

, 2022
Majority of patients with breast cancer were diagnosed with locally advanced stages of the disease (54%). This study aimed to explain the pathological response received to neoadjuvant chemotherapy (NACT) according to the molecular classification of ...
Demirelli, Hulusi Fuat, ALKAN, Gülin, Derin, Sumeyra, Kacar, Ezgi, DEMİRCİ, NEBİ SERKAN, ŞENTÜRK ÖZTAŞ, NİHAN, VALIKHANOVA, NAHIDA, Sarac, Betul, Bedir, Sahin, DEĞERLİ, EZGİ, TURNA, ZEYNEP HANDE   +10 more
core   +1 more source

Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus

, 2013
AIM: To assess tumour regression grade (TRG) and lymph node downstaging to help define patients who benefit from neoadjuvant chemotherapy.METHODS: Two hundred and eighteen consecutive patients with adenocarcinoma of the esophagus or gastro-esophageal ...
Kelly, Jamie, Iveson, T., Underwood, T.J., Rees, Charlotte, Bailey, Ian, Bateman, Andrew R., Byrne, James, Sharland, Donna, Noble, Fergus, Bateman, Adrian C., Nolan, Luke   +10 more
core   +1 more source

Efficacy and safety of neoadjuvant treatment with chemotherapy and immune checkpoint blockades for potentially resectable gastric cancer: A retrospective study

Human Vaccines & Immunotherapeutics
The efficacy and safety of adding immune checkpoint inhibitors (ICIs) to neoadjuvant chemotherapy in patients with potentially resectable gastric cancer (GC) are uncertain.
Huiyun Wang, Xuchen Zhang, Yulong Tian, Haitao Jiang, Ning Liu, Jinfeng Zhan, Yunqing Chen, Shanai Song, Xiao Huang, Man Jiang, Chuantao Zhang, Helei Hou   +11 more
doaj   +1 more source

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Frontiers in Oncology, 2023
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in the treatment landscape of non-small cell lung cancer (NSCLC).
Qin Wang, Chen Qi, Jing Luo, Nan Xu, Mao-tian Xu, Yong Qiang, Chi Zhang, Yi Shen   +7 more
doaj   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
Jens Huober, Reinisch, Mattea, Sibylle Loibl, Silvia Darb-Esfahani, Michael Untch, Hans Tesch, Martin-Leo Hansmann, Jan C Brase, Knut Engels, Judith Prinzler, Keyur Mehta, Minckwitz, Gunter von, Brase, Jan C., Kronenwett, Ralf, Hansmann, Martin-Leo, Huober, Jens, Engels, Knut, Solbach, Christine, Tesch, Hans, Carsten Denkert, Denkert, Carsten, Gunter von Minckwitz, Bruno V Sinn, Loibl, Sibylle, Mattea Reinisch, Peter A Fasching, Sinn, Bruno V., Ralf Kronenwett, Christine Solbach, Prinzler, Judith, Mehta, Keyur, Fasching, Peter Andreas, Untch, Michael, Denkert, Carsten Michael, Darb-Esfahani, Silvia   +34 more
core   +1 more source

Survival analysis stratified by neoadjuvant chemotherapy regimen.

, 2021
(A) Kaplan-Meier curves for overall survival stratified by neoadjuvant chemotherapy regimen. (B) Kaplan-Meier curves for cancer specific survival stratified by neoadjuvant chemotherapy regimen.
Artur Lemiński (11642863), Tomasz Byrski (11642869), Krystian Kaczmarek (11642866), Marcin Słojewski (204584)   +3 more
core   +1 more source

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis

World Journal of Surgical Oncology, 2021
Background Hepatectomy for resectable colorectal liver metastasis (CRLM) is recommended. However, the efficacy of upfront hepatectomy without neoadjuvant chemotherapy (NAC) is unclear due to the uncertainty of perioperative systemic chemotherapy ...
Kosuke Ono, Tomoyuki Abe, Akihiko Oshita, Yusuke Sumi, Takuya Yano, Hiroshi Okuda, Manabu Kurayoshi, Tsuyoshi Kobayashi, Hideki Ohdan, Toshio Noriyuki, Masahiro Nakahara   +10 more
doaj   +1 more source

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC

Pakistan Journal of Medical Sciences, 2021
Objective: To evaluate the clinical effects of apatinib combined with DOS regimen in the neoadjuvant chemotherapy for locally advanced gastric cancer (LAGC). Methods: Eighty patients with LAGC admitted to Baoding first Central Hospital from January 2018 to October 2020 were randomly divided into two groups (n=40, respectively).
Zhou, Peng-zhe, Gao, Lei, Wu, Wei, Hao, Ying-xia   +3 more
openaire   +3 more sources

Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

, 2015
Purpose: There is a need to identify more sensitive clinico-pathological criteria to assess the response to Neo-ACT and guide subsequent adjuvant-therapy.
Ball, G., Palmer, D., Pinder, S., MacMilan, RD, Moseley, Paul M., MacMilan, R. D., Pinder, Sarah; id_orcid, Latham, B, Ellis, I., Cornford, Eleanor, Ball, G, Price, James, Moseley, PM, Lee, A. H. S., Ball, Graham, Chan, A, Chan, SYT, Chan, S. Y. T., Abdel-Fatah, TM, Palmer, David, Latham, Bruce, Silverman, R, Moseley, P. M., Chan, Arlene, Palmer, D, Cornford, E, MacMilan, R., Price, J., Chan, A., Cornford, E., Ellis, IO, Abdel-Fatah, Tarek M., Lee, AHS, Ellis, I. O., Pinder, S, Moseley, P., Latham, B., Abdel-Fatah, T. M., Silverman, Rafael, Lee, A., Lee, Andrew H S, MacMilan, R. Douglas, Ellis, Ian O., Chan, Stephen Y T, Silverman, R., Abdel-Fatah, T., Chan, S., Price, J   +47 more
core   +1 more source

Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience

PLoS ONE, 2021
Introduction Neoadjuvant chemotherapy has become standard of care for cisplatin-eligible patients with muscle-invasive bladder cancer qualified to radical cystectomy, providing a modest increase in 5-year overall survival rate. Several regimens are being
Artur Lemiński, Krystian Kaczmarek, Tomasz Byrski, Marcin Słojewski   +3 more
doaj   +2 more sources